Cite
Are anti-PD-1-associated immune related adverse events a harbinger of favorable clinical prognosis in patients with gastric cancer?
MLA
Zhang, Xiaoyun, et al. “Are Anti-PD-1-Associated Immune Related Adverse Events a Harbinger of Favorable Clinical Prognosis in Patients with Gastric Cancer?” BMC Cancer, vol. 22, no. 1, Nov. 2022, pp. 1–9. EBSCOhost, https://doi.org/10.1186/s12885-022-10199-x.
APA
Zhang, X., Xu, S., Wang, J., Lv, Y., Wang, N., Lai, R., Sha, Z., Zhao, Q., & Guo, Z. (2022). Are anti-PD-1-associated immune related adverse events a harbinger of favorable clinical prognosis in patients with gastric cancer? BMC Cancer, 22(1), 1–9. https://doi.org/10.1186/s12885-022-10199-x
Chicago
Zhang, Xiaoyun, Shuo Xu, Jiaqi Wang, Yalei Lv, Na Wang, Ruixue Lai, Ziyue Sha, Qun Zhao, and Zhanjun Guo. 2022. “Are Anti-PD-1-Associated Immune Related Adverse Events a Harbinger of Favorable Clinical Prognosis in Patients with Gastric Cancer?” BMC Cancer 22 (1): 1–9. doi:10.1186/s12885-022-10199-x.